| Name: | Dexamethasone Acetate EP Impurity C |
| Catalogue No. | VL273019 |
| CAS No. | N/A |
| Molecular Formula | C24H31FO6 |
| Molecular Weight | 434.5 |
| Status | In-stock |
| IUPAC Name | 9-fluoro-11β,17β-dihydroxy-16α-methyl-3,20-dioxopregna-1,4-dien-21-yl acetate |
| Appearance | White Powder |
| Description | Dexamethasone Acetate EP Impurity C or 9-fluoro-11β,17β-dihydroxy-16α-methyl-3,20-dioxopregna-1,4-dien-21-yl acetate is a debasement of Dexamethasone. Dexamethasone drug delivery system (DDS) was later developed as a biodegradable intravitreal implant to give a sustained delivery of 700 μg of dexamethasone to the retina and vitreous and is sanctioned by the FDA. |
| References | Dongala, Thirupathi, et al. “Stability Indicating LC Method Development for Hydroxychloroquine Sulfate Impurities as Available for Treatment of COVID-19 and Evaluation of Risk Assessment prior to Method Validation by Quality by Design Approach.” Chromatographia, vol. 83, no. 10, Aug. 2020, pp. 1269–81,https://doi.org/10.1007/s10337-020-03945-5.London, Nikolas J. S., et al. “The Dexamethasone Drug Delivery System: Indications and Evidence.” Advances in Therapy, vol. 28, no. 5, Mar. 2011, pp. 351 |
![(16α)-21-[(Ethoxycarbonyl)oxy]-17-hydroxy-16-methylpregna-1,4,9(11)-triene-3,20-dione](/public/site/files/site_images/thumb_16alpha-21-ethoxycarbonyl-oxy-17-hydroxy-16-methylpregna-1-4-9-11-triene-3-20-dione47031.png)